Introduction: The authors investigated whether a new ginkgo biloba (ginkgo) fresh plant extract had a positive effect on microcirculation in the skin and liver of elderly individuals, and whether the extract had antioxidative properties in vivo. Methods: In a monocentric, controlled clinical trial with 32 elderly patients, 16 patients received three 90 mg ginkgo extract tablets twice daily for 30 days, and 16 patients acted as untreated controls. On days 0, 10, 20, and 30, microcirculatory parameters were measured using intravital microscopy in combination with reflection spectrometry, and the amount of reduced glutathione in the liver. Results: This new ginkgo fresh plant extract significantly increased the number of blood cell-perfused nodal points, the venular streaming flow, and the local hematocrit in treated participants compared to control participants and compared to values on day 0. The ginkgo preparation also increased microcirculation in the liver, and possessed antioxidative properties that resulted in significant increases in the amount of the radical scavenger glutathione in treated participants. Conclusion: The new ginkgo fresh plant extract increased the microcirculation significantly, and at the same time improved the radical scavenging capacity in elderly patients and was very well tolerated. This extract is an interesting adjuvant treatment option for patients suffering from impaired microcirculation and improves mechanisms which inhibit an accelerated expression of atherosclerosis.
INTRODUCTION
Preparations of ginkgo biloba (ginkgo) are among the most widely researched and top-selling phytopharmaceuticals, 1 and are often used in elderly patients. Ginkgo has been investigated for the treatment of mildto-moderate dementia symptoms, its ability to increase mental performance, and for cerebral insufficiency, tinnitus, vertigo, and peripheral arterial occlusive disease. 2 The mode of action of ginkgo varies; in animal experiments, ginkgo preparations showed vasoregulatory activity, 3 leading to improved rheological properties in the blood. In humans, individuals with ginkgo had enhanced peripheral and coronary blood flow as a result of endothelium-dependent vasodilation. 4 Furthermore, more than 20 papers have described the in vitro antioxidative effects of gingko, which appears to protect endothelial cells. 5 However, ginkgo also inhibits plateletactivating factors, decreases the age-related loss of muscarinic cholinoreceptors, stimulates choline uptake in the hippocampus, and inhibits beta-amyloid deposition. 6 Several studies have investigated the ability of ginkgo to increase the microcirculatory perfusion of blood vessels. In rats, cerebral microcirculation after subarachnoid hemorrhage, 7 as well as the hepatic microcirculation in warm ischemia, 8 was increased after intravenous or oral administration of ginkgo extract, and ginkgo may also have a protective effect on hepatic microcirculation in rats with induced liver injuries. 9 Two clinical trials in elderly patients with either pathological viscoelasticity values 10 or poor cerebral circulation 11 showed that intravenous application of a ginkgo extract lead to a dose-dependent increase in microcirculation in the skin after acute application, or in the bulbar conjunctiva after 10-15 days. Two trials with orally administered ginkgo tablets in healthy volunteers showed an increase in cutaneous microcirculation after acute intake, 12 and an increase in forearm blood flow after 6 weeks. 13 Currently, most studies use a single standardized ginkgo extract using acetone as an extractant (60%) and with a drug extraction ratio of 35-67:1. The authors developed a new ginkgo extract made from fresh leaves using a more traditional approach by using ethanol 65% as extractant and with a drug extraction ratio of 3-5:1. This extract was shown to have positive effects on retinal blood flow in healthy volunteers after acute application in a clinical pilot trial. 14 To the authors knowledge, this is the first trial on ginkgo to assess not only changes in the microcirculation of the gingiva or skin in response to ginkgo, but also in a large inner organ such as the liver. Moreover, the authors believe that this is also the first investigation of whether the antioxidant activity of ginkgo observed in vitro can be demonstrated in vivo by measuring the amount of reduced glutathione. 
MATERIALS AND METHODS

Patients
Study Medication
Patients were issued one bottle with 180 tablets and told to take three tablets with water twice daily; once in the morning and once in the Eligible participants were investigated at day 0 which served as the baseline value, and at days 10, 20, and 30. Two hours prior to the investigation, participants were not allowed to drink alcohol, coffee, tea, or caffeinated carbonated beverages, they were to have had at least 6 hours of sleep the previous night, and sufficient acclimatization and rest (normal blood pressure, respiratory rate, and heart frequency).
The measurements were taken while the participants were seated. A more detailed description of the instruments, methods, and technologies that were used in this study can be found in other papers. 15, 16 The At the end of the treatment period, the participants were assessed to determine if their condition had improved, remained the same, or
worsened. In addition, participants reported any adverse events at each visit.
Statistical Analysis
The authors determined the differences within both groups between the different time points 
RESULTS
Demographic Data
The demographic data of the study population are listed in Table 1 . The treatment and control groups were similar in age, height, weight, body mass index, and gender distribution, and were therefore comparable. All of the participants came to all of the study visits, and in the treatment group they were fully compliant regarding intake of the study medication.
Efficacy and Safety Parameters
The mean number of blood cell-perfused n NP increased in the ginkgo group from 60 to 64. furthermore, the C ICAM-1 was significantly higher compared to both the baseline value and to the Figure 4 . Relative changes in current flow in the sinusoids (Q sin ) in the liver in a defined network unit during the treatment period of 30 days in participants taking ginkgo tablets (n=16) and in untreated controls (n=16). *A statistically significant difference between the ginkgo and control group (P<0.05). To assess changes in antioxidative properties, the authors measured the amount of reduced hepatic glutathione C GI-red . Ginkgo appeared to improve the antioxidative capacity of the body: after 10 days, there was an increase in the C GI-red , which continued to increase up to day 30, and was significantly different from the baseline value and the control group from day 20 onwards (P<0.05) ( Figure 6 ).
Of the 16 patients in the control group at the end of the treatment, 11 described their state of health as unchanged, four described it as worse, and one described it as improved. In the ginkgo group, five participants described their state as unchanged, two described it as worse, and nine described it as improved. The tablets were well tolerated and no side effects were reported during the treatment period. In rats, an increase in blood perfusion after ginkgo application was attributed to regulation of the precapillary sphincter and to dilation of perfusion capillaries, 18 and in the blood of eight patients taking a ginkgo preparation for 2 months, concentrations of the vasodilating molecules, cyclic adenosine monophosphate (cAMP), and cyclic guanosine monophosphate (cGMP) were significantly increased compared to baseline. 19 The extent to which inhibition of a platelet activating factor (PAF) 20 The active constituents of ginkgo that are responsible for its pharmacological effects are mostly flavonoids, terpenoids, such as ginkgolide A, B, and C, and bilobalides. 2 Although ginkgo was used traditionally as a tea, 21 19 with friendly permission of Springer Verlag, Vienna, which also owns the copyright for this figure.
DISCUSSION
(bilobalide and ginkgolide A and B) that were similar to the standardized extract; these constituents may be the basis for the rapid increase in retinal blood flow. 23 In another trial in elderly patients with age-related non-Alzheimer mild cognitive impairment, daily intake of two tablets containing 90 mg each of the ginkgo fresh plant extract was associated with an improvement in the SF-12 quality-of-life mental health subscore.
Furthermore, treated patients had decreased memory impairment and increased ability to concentrate; in this study, the extract was well tolerated. 24 The study on the retinal blood flow 14 showed a good efficacy between 90 and 270 mg extract, and the bioavailability trial showed a higher amount of active constituents in the blood than as if a patient would take a ginkgo tincture. 23 Thus, a dosage scheme of 2x 90 mg extract daily was chosen, which proved to be safe and effective in the above mentioned trial in elderly patients. 24 An important finding of this study was that the ginkgo preparation used was associated with a two-fold increase in the amount of insufficiency, 27 hypertension, insulin resistance, and sepsis, 28 and it is believed to play a role in metabolic syndrome, 29 Raynaud syndrome, 30 and erectile dysfunction. 31 Microcirculation is generally decreased in smokers, 32 and most likely also in patients with cognitive disorders. 33 Furthermore, as people age, perfusion decreases;
thus, elderly persons in particular have impaired microcirculation. 34 Ginkgo has a very good safety record 2,21 and the good tolerability of this ginkgo extract has been seen in all the trials which have been carried out so far. 14, 23, 24 Thus, taking ginkgo to improve perfusion of the capillary networks in the entire body may be a good preventative measure or an adjuvant treatment option for people with impaired microcirculation. 
CONCLUSION
